Virnich Daniel
SEC CIK 1891107 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| STLN | Starling Oncology, Inc. | Pres | 2.34M | $23.5K | $7,647 | 23 | 2021-11-12 | 2026-05-21 |
Most active insiders at STLN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chernett Jorey | 10% | $2.69M | — |
| 2 | Hively Brad | Dir | — | $2.00M |
| 3 | Kaushal Mohit | Dir | — | $335.1K |
| 4 | Podnos Yale | Chief Medical Off | — | $276.4K |
| 5 | Pacala Mark L | Dir | — | $200.0K |
| 6 | Carter Robert Ross | CFO | — | $879.32 |
| 7 | England Kristin | Chief Administrative Off | — | — |
| 8 | Langsam Jeffrey | Chief Clinical Off | — | — |
| 9 | Ling Gabriel | Dir | — | — |
| 10 | TOI M, LLC | Dir | — | — |
| 12 | Virnich Daniel | CEO | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 17:37 | 2026-05-21 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | J - Other | $4.47 | -23.1K | 2.34M | -1.0% | -$103.1K | |
| 2026-04-01 20:46 | 2026-03-27 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | A - Grant | $0.00 | -670.6K | 2.46M | -21% | $0 | |
| 2026-04-01 20:46 | 2026-03-27 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | J - Other | $3.07 | -98.5K | 2.36M | -4% | -$302.5K | |
| 2026-03-18 | 2026-03-17 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | J - Other | $3.59 | -11.8K | 1.79M | -0.7% | -$42.5K | |
| 2025-11-19 | 2025-11-17 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | A - Grant | $0.00 | +6,464 | 1.80M | +0.4% | $0 | |
| 2025-11-14 | 2025-11-12 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | A - Grant | $0.00 | +6,211 | 1.79M | +0.3% | $0 | |
| 2025-05-22 | 2025-05-21 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | D - Sale to Iss | $2.68 | -20.4K | 1.79M | -1% | -$54.6K | |
| 2025-04-02 | 2025-03-31 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | A - Grant | $0.00 | +1.08M | 1.81M | +150% | $0 | |
| D | 2025-03-28 | 2025-03-26 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | P - Purchase | $1.04 | +22.6K | 724.4K | +3% | +$23.5K |
| 2025-03-20 | 2025-03-19 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | D - Sale to Iss | $0.89 | -10.3K | 701.7K | -1% | -$9,132 | |
| M | 2024-11-21 | 2024-11-20 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | D - Sale to Iss | $0.14 | -9,727 | 717.0K | -1% | -$1,362 |
| M | 2024-11-18 | 2024-11-12 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | J - Other | $0.00 | -195.2K | 838.9K | -19% | $0 |
| D | 2024-05-23 | 2024-05-21 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | D - Sale to Iss | $0.6 | -11.2K | 718.4K | -2% | -$6,704 |
| D | 2024-05-23 | 2024-05-21 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | A - Grant | $0.00 | +198.5K | 916.9K | +28% | $0 |
| 2023-11-22 | 2023-11-21 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | D - Sale to Iss | $2.19 | -4,322 | 729.6K | -0.6% | -$9,465 | |
| 2023-11-16 | 2023-11-14 | STLN | Starling Oncology, Inc. | Virnich Daniel | CEO | D - Sale to Iss | $2.39 | -4,604 | 733.9K | -0.6% | -$11.0K | |
| D | 2023-03-21 | 2023-03-17 | STLN | Starling Oncology, Inc. | Virnich Daniel | Pres | A - Grant | $0.00 | +114.9K | 738.5K | +18% | $0 |
| DM | 2022-12-08 | 2022-12-07 | STLN | Starling Oncology, Inc. | Virnich Daniel | Pres | M - OptEx | $0.86 | +350.0K | 623.6K | +128% | +$301.0K |
| A | 2022-11-22 | 2022-11-15 | STLN | Starling Oncology, Inc. | Virnich Daniel | Pres | S - Sale | $2.03 | -3,767 | 233.5K | -2% | -$7,647 |
| D | 2022-11-21 | 2022-11-17 | STLN | Starling Oncology, Inc. | Virnich Daniel | Pres | A - Grant | $0.00 | +40.1K | 273.6K | +17% | $0 |
| 2022-11-17 | 2022-11-15 | STLN | Starling Oncology, Inc. | Virnich Daniel | Pres | D - Sale to Iss | $2.03 | -3,767 | 233.5K | -2% | -$7,647 | |
| D | 2022-03-23 | 2022-03-21 | STLN | Starling Oncology, Inc. | Virnich Daniel | Pres | A - Grant | $0.00 | +42.0K | 237.3K | +22% | $0 |
| DM | 2021-11-16 | 2021-11-12 | STLN | Starling Oncology, Inc. | Virnich Daniel | COO | A - Grant | $0.00 | +195.2K | 195.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations